600763 Topchoice Medical
- 64.21
- +0.30+0.47%
Topchoice Medical News
Tongze Healthcare (600763): First-quarter results slightly exceeded expectations, and accelerated implant delivery can be expected
Event: Achieved revenue of 2,847 million yuan (+4.7%), net profit of 500 million yuan (-8.72%), net profit of non-return to mother of 481 million yuan (-8.37%) in 2023; achieved revenue in Q4
The actual controller of “Ya Mao” received another warning letter and the financial grant was overdue twice
① Lu Jianming, the actual controller of Ophthalmology Investment and the actual controller of Tongce Medical's participating company, received a warning letter from the Zhejiang Securities Regulatory Bureau; ② Ophthalmology Investment failed to promptly return 112 million yuan of financial aid provided by Tongce Medical from 2019 to August 2020; ③ Ophthalmology Investment and Lu Jianming's actions were recorded in the securities and futures market integrity file.
Express News | General Medical Treatment: Received a decision on administrative supervision measures from the Zhejiang Securities Regulatory Bureau
Tongze Healthcare (600763): Demand for diagnosis and treatment is growing steadily, and various businesses are developing steadily
Event: The company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 2,847 billion yuan, a year-on-year increase of 4.70%; net profit to mother was 500 million yuan, a year-on-year decrease of 8 billion yuan.
General Medicine (600763.SH): Some affiliated hospitals already use implant navigation devices when receiving difficult cases
Gelonghui, May 8 | Tongze Medical (600763.SH) said on an interactive platform that some hospitals belonging to the company have used implantation navigation equipment when receiving difficult cases, and the specific equipment procurement plans are determined according to each hospital's own situation.
Tongze Healthcare (600763.SH): A total of 9241,000 shares were repurchased through centralized bidding
On May 7, Ge Longhui Medical (600763.SH) announced that up to now, the company has repurchased 115,500 shares of the company's shares through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 0.0360% of the company's total share capital, and the transaction amount is 7,756,221 yuan. In 2023, the company repurchased 808,600 shares, which were stored in the company's special repurchase securities account. The original plan was to use the company's employee share incentives or shareholding plans. Overall, the company's repurchase account had a total of 924,100 shares, accounting for 0.28 of the company's total share capital
Tongze Healthcare (600763): Performance is in line with expectations, rapid implant placement after collection
Guide to this report: In the short term, due to the downturn in consumption and the collection of dental implants, the revenue growth rate increased slightly, and the performance was in line with expectations. The company actively expands and develops the Dandelion Branch and further explores new models of mergers, acquisitions and franchise expansion. Maintain an increase in holdings rating. Key investment points:
Tongze Healthcare (600763): Performance continues to be pressured and the impact of collection is gradually being digested
Core view: Tongze Healthcare announces 2023 and 2024Q1 results. The company achieved operating income of 2,847 billion yuan in 2023, +4.70% year on year; net profit to mother of 500 million yuan, -8.72 million yuan year on year
Tongce Healthcare (600763) 2023 Report & 2024 First Quarter Review: The impact of collection is gradually digesting the 2024 growth trend improvement
Incident: In 2023, the company achieved total operating revenue of 2,847 billion yuan (+4.70%, indicating year-on-year growth rate, same below), net profit of 500 million yuan (-8.72%) to mother, net profit of 481 million yuan (-
Analysts Are More Bearish On Topchoice Medical Co., Inc. (SHSE:600763) Than They Used To Be
The analysts covering Topchoice Medical Co., Inc. (SHSE:600763) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Bot
Tongce Healthcare (600763) Annual Report & Quarterly Report Review: Stable Q1 performance, full year results are expected to continue to recover
Incident: The company released its 2023/2024Q1 performance report, achieving revenue of 2,847/708 million yuan (+4.7%/+5.0%), respectively, and net profit attributable to shareholders of listed companies of 5.00
Tongze Healthcare (600763): Steady growth in 1Q24, optimistic about the upward trend throughout the year
1Q24 The company's performance achieved steady growth. The company achieved revenue/net profit of 2,85/50 billion yuan (yoy +4.7%/-8.7%) in 23, and achieved revenue/net profit to mother 7.1/1.7 in 1Q24
Is Topchoice Medical Co., Inc.'s (SHSE:600763) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Most readers would already be aware that Topchoice Medical's (SHSE:600763) stock increased significantly by 14% over the past week. Since the market usually pay for a company's long-term fundamental
The Topchoice Medical Co., Inc. (SHSE:600763) First-Quarter Results Are Out And Analysts Have Published New Forecasts
The analysts might have been a bit too bullish on Topchoice Medical Co., Inc. (SHSE:600763), given that the company fell short of expectations when it released its first-quarter results last week.
Tongze Healthcare (600763): The impact of short-term pressure collection on the profit side is gradually being digested
Matters: The company released its 2023 annual report: achieved revenue of 2,847 million yuan (+4.70%), net profit of 500 million yuan (-8.72%) to mother, deducted non-net profit of 481 million yuan (-8.37%). Fourth quarter order
Tongze Healthcare (600763): Business is gradually stabilizing and waiting for an inflection point
Performance summary: The company released its 2024 quarterly report and 2023 annual report. The first quarter of 2024 achieved revenue of 710 million yuan (+5%), net profit attributable to mother of 170 million yuan (+2.5%), or approximately 170 million yuan after deduction
Tongce Healthcare (600763.SH) announced its 2023 annual results, and net profit of 500 million yuan decreased by 8.72% year-on-year
Tongce Healthcare (600763.SH) released the 2023 annual performance report. The company achieved operating income of 2 during the reporting period...
Express News | Tongce Healthcare: Net profit from mother in the first quarter was 173 million yuan, up 2.51% year-on-year
General Medicine (600763): The number of outpatients is recovering steadily, and collection helps increase the number of dental implants
Brief performance review On April 25, 2024, the company released its 2023 annual report. In 2023, the company achieved revenue of 2,847 billion yuan (+5% year over year) and net profit of 500 million yuan (-9% year over year)
Express News | Tongze Healthcare: Plans to repurchase shares of 30 million yuan to 50 million yuan
Analysis
Price Target
No Data
